CRAIGAVON-headquartered pharmaceuticals group Almac has reported double-digit percentage rises in sales and profits in what is is lauding as its "most successful financial year ever".
And in tandem with those figures, it says its global workforce has now reached 7,000 people - a total growth of more than 1,000 in just 18 months.
In the year to September 30 the global contract pharmaceutical development and manufacturing organisation saw its sales soar to £840 million.
That's a 14.3 per cent rise - or £105m in monetary terms - on the 2021 figure of £735m.
And pre-tax profits rose by 20 per cent to £97m from £81m in the same period the previous year.
The rise in staff numbers, aligned with the current capital investment programme, means Almac is well on its way to delivering on the significant expansion plans first announced in November 2021.
Almac is at the forefront of developing, manufacturing, testing and distributing essential medicines to patients around the world.
During its latest financial year the group was involved in the development of hundreds of life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy and neurology.
The group, which is owned by a charitable trust named after its founder Sir Allen McClay, maintains a long-held policy of reinvesting 100 per cent of group profits back into the business.
Almac chairman and chief executive Alan Armstrong said: “The announcement of these results is a welcome continuation of growth for the group, and I to thank all within the organisation for playing their part.
“We are committed to reinvesting all our profits in the business, this success will play a vital part in our continued growth, expansion, and increase in our employee numbers.”
He added: “Almac is dedicated to ensuring we remain a global leader in our industry, giving our clients and ultimately patients across the world the best possible offering.
“We continue to play our part as a valued and trusted member of the communities in which we operate.”
Last November Almac announced plans to invest £200 million in a massive global capital programme over the next three years to meet growing demand for its business.
